20-F: IM Cannabis Corp. Announces Financial Results and Strategic Shifts in 2024

IM Cannabis Corp. reports its 2024 financial results, highlighting a strategic focus on the German market and cost-saving measures.

Summary

• IM Cannabis Corp. (IMCC) reported its financial results for the year ended December 31, 2024, showcasing a strategic shift towards the German cannabis market.
• The company is focusing on achieving profitability in 2025.
• Consolidated revenues for 2024 were $54.03 million, an 11% increase compared to $48.80 million in 2023.
• The increase in revenue is mainly attributed to accelerated growth in Germany's revenue of $10.02 million or 183% and decreased Revenue in Israel of $4.793 net.
• Gross profit for 2024 was $8.45 million, a decrease of 14% compared to $9.85 million in 2023.
• The company experienced a net loss of $11.77 million in 2024, compared to a net loss of $10.23 million in 2023.
• The company is managing its cash flow daily and will look for external funding for its operations.
• The company is managing its cash flow daily and will look for external funding for its operations.
• The company is managing its cash flow daily and will look for external funding for its operations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is revenue growth, there are also increased losses and concerns about liquidity and the ability to continue as a going concern. The strategic shift towards Germany is a positive, but the risks and uncertainties temper the overall outlook.

Positives

• The company's consolidated revenues for 2024 were $54.03 million, an 11% increase compared to $48.80 million in 2023.
• The increase in revenue is mainly attributed to accelerated growth in Germany's revenue of $10.02 million or 183% and decreased Revenue in Israel of $4.793 net.
• The company is focusing on achieving profitability in 2025.
• The company is managing its cash flow daily and will look for external funding for its operations.

Negatives

• Gross profit for 2024 was $8.45 million, a decrease of 14% compared to $9.85 million in 2023.
• The company experienced a net loss of $11.77 million in 2024, compared to a net loss of $10.23 million in 2023.

Risks

• The company may not be able to secure the funds necessary to implement its strategies.
• Increased competition could materially and adversely affect the business, financial condition and results of operations of the Group.
• The Group is vulnerable to the political, economic, legal, social, regulatory, and military conditions affecting Israel and the Middle East that could have a material adverse effect on the Groups business, results of operations, financial condition and prospects.
• The Group is vulnerable due to the results of the Anti-Dumping investigation into cannabis imports from Canada that could have a material adverse effect on the Groups business.
• The Company may not be able to continue as a going concern.

Future Outlook

The Company is focusing on achieving profitability in 2025.

Industry Context

The document provides insight into the competitive landscape of the cannabis industry, particularly in Israel and Germany, highlighting the importance of regulatory expertise, brand recognition, and supply chain management.

Management Changes

Legal Proceedings

• The Company is involved in ongoing legal proceedings, including a class action lawsuit and disputes related to COVID-19 test kits.
• The Company is subject to an ongoing anti-dumping investigation by the Israeli Ministry of Economy and Industry into cannabis imports from Canada.

Related Party Transactions

• Oren Shuster, the CEO, subscribed for an aggregate of $237,214 of May 2024 Debentures in the May 2024 Private Placement.
• Mr. Oren Shuster, Mr. Shmulik Arbel, and Mr. Rafael Gabay, each participated in the November 2024 Offering.
• The Company completed a debt settlement in the amount of US$560,000 with Mr. Oren Shuster.

Stakeholder Impact

• The company's financial performance and strategic decisions will impact shareholders, employees, customers, and suppliers.
• The company's ability to continue as a going concern is a key factor affecting all stakeholders.

Next Steps

• The Company will continue to evaluate additional sources of capital and financing.
• The Company will continue to enhance its cybersecurity protocols and third-party risk management framework to mitigate potential future threats.

Key Dates

Keywords

cannabis, medical cannabis, financial results, Germany, Israel, revenue, profitability, IM Cannabis Corp